After he orchestrated the development and sale of Zytiga to J&J (for $1B), has Alan Auerbach struck gold again after Puma's successful phase III testing for the HER-2 positive breast cancer therapy, the rights to which he secured from Pfizer?
http://www.bloomberg.com/news/2014-07-22/puma-biotechnology-soars-on-breast-cancer-drug-results.html
http://www.fiercebiotech.com/story/cougar-founder-snags-pfizer-cancer-drug-raises-55m-and-launches-new-biotech/2011-10-06
http://www.bloomberg.com/news/2014-07-22/puma-biotechnology-soars-on-breast-cancer-drug-results.html
http://www.fiercebiotech.com/story/cougar-founder-snags-pfizer-cancer-drug-raises-55m-and-launches-new-biotech/2011-10-06
No comments:
Post a Comment